數位治療市場機會、成長動力、產業趨勢分析和 2024 年至 2032 年預測

全球數位治療市場將於2023 年達到89 億美元，預計2024 年至2032 年複合年成長率為31.5%。中的日益整合。數位療法利用經過臨床驗證的軟體直接向患者提供醫療干預措施，幫助治療和管理各種健康狀況。

對管理慢性病的創新解決方案以及預防保健和健康療法的需求不斷成長，是一個關鍵的市場驅動力。對個人化醫療保健的日益關注以及具有健康意識的個人數量的不斷增加擴大了對 DTx 的需求，為其未來的擴張奠定了堅實的基礎。

市場分為軟體和設備，到 2032 年，軟體部分預計將以 31.7% 的複合年成長率成長。 。這些平台符合以患者為中心的醫療保健的轉變以及數據驅動的治療策略日益重要的趨勢。改進的分析能力也支持客製化的治療計劃，提高患者的治療效果。

根據應用，數位治療市場分為糖尿病、心血管疾病、肥胖、高血壓、心理健康和失眠。其中，在全球糖尿病盛行率不斷上升的推動下，糖尿病細分市場預計在 2024 年至 2032 年期間將以 31% 的複合年成長率成長。數位療法透過提供即時監測、藥物追蹤和生活方式指導的工具在糖尿病管理中發揮著至關重要的作用，從而提高依從性和患者的整體健康狀況。

北美將在2023 年主導數位治療市場，預計2024 年至2032 年複合年成長率為30.7%。政策。美國在該地區處於領先地位，私營和公共部門都進行了大量投資，進一步推動了 DTx 解決方案的採用。該地區的醫療保健提供者擴大將數位療法整合到護理計劃中，以改善患者的治療效果並降低醫療成本。

隨著技術的不斷進步和支持性的監管框架，北美有望保持在數位治療市場的前沿，為創新和採用樹立基準。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性病盛行率增加
    • 成本控制的需求不斷增加
    • 提高護理服務品質的潛力
    • 數位療法日益普及
  • 產業陷阱與挑戰
    • 安全和隱私問題
    • 缺乏熟練的 IT 專業人員
• 成長潛力分析
• 監管環境
  • 美國
  • 歐洲
• 技術景觀
  • 核心技術
  • 鄰近技術
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場：按組成部分，2018 - 2032

• 主要趨勢
• 軟體
• 裝置

第 6 章：市場：依應用分類，2018 - 2032

• 主要趨勢
• 糖尿病
• 肥胖
• 心血管
• 心理和行為健康
• 高血壓
• 失眠
• 其他

第 7 章：市場：依銷售管道分類，2018 - 2032

• 主要趨勢
• 企業對企業 (B2B)
• 企業對消費者 (B2C)

第 8 章：市場：按地區分類，2018 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
• MEA
  • 南非
  • 沙烏地阿拉伯

第 9 章：公司簡介

• Otsuka Holdings Co., Ltd
• LifeScan Inc.
• Teladoc Health
• Omada Health Inc.
• Pear Therapeutics, Inc.
• Propeller Health (ResMed)
• Teladoc Health

The Global Digital Therapeutics Market reached USD 8.9 billion in 2023 and is projected to grow at a CAGR of 31.5% from 2024 to 2032. This remarkable growth is fueled by rapid advancements in healthcare technology and the increasing integration of digital health solutions in managing chronic diseases. Digital therapeutics leverage clinically validated software to deliver medical interventions directly to patients, aiding in the treatment and management of various health conditions.

Rising demand for innovative solutions to manage chronic diseases, alongside preventive care and wellness therapies, is a key market driver. A growing focus on personalized healthcare and the increasing number of health-conscious individuals amplify the demand for DTx, setting a strong foundation for its future expansion.

The market is segmented into software and devices, with the software segment anticipated to grow at a CAGR of 31.7% through 2032. Software-based DTx solutions, primarily accessed via mobile applications, offer unparalleled convenience by enabling real-time feedback, remote monitoring, and personalized care. These platforms align with the shift towards patient-centric healthcare and the rising importance of data-driven treatment strategies. Improved analytics capabilities also support tailored therapeutic plans, enhancing patient outcomes.

Based on application, digital therapeutics market is classified into across diabetes, cardiovascular diseases, obesity, hypertension, mental health, and insomnia. Among these, the diabetes segment is expected to grow at a CAGR of 31% during 2024-2032, driven by the increasing global prevalence of diabetes. Digital therapeutics play a crucial role in managing diabetes through tools that offer real-time monitoring, medication tracking, and lifestyle guidance, thereby improving adherence and overall patient health.

North America dominated the digital therapeutics market in 2023, with a projected CAGR of 30.7% from 2024 to 2032. Factors contributing to this dominance include a well-established healthcare infrastructure, widespread adoption of smartphones, and regulatory policies that foster digital health innovation. The U.S. leads the region with substantial investments from both private and public sectors, further driving the adoption of DTx solutions. Healthcare providers in the region increasingly integrate digital therapeutics into care plans to enhance patient outcomes and lower healthcare costs.

With continuous advancements in technology and a supportive regulatory framework, North America is poised to remain at the forefront of the digital therapeutics market, setting benchmarks for innovation and adoption.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Rising need for cost containment
    • 3.2.1.3 Potential to increase quality of care delivery
    • 3.2.2.4 Growing popularity of digital therapeutics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Security and privacy issues
    • 3.2.2.2 Lack of skilled IT professionals
• 3.3 Growth potential analysis
  • 3.3.1 By component
  • 3.3.2 By application
  • 3.3.3 By sales channel
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market, By Component, 2018 - 2032 (USD Million)

• 5.1 Key trends
• 5.2 Software
• 5.3 Device

Chapter 6 Market, By Application, 2018 - 2032 (USD Million)

• 6.1 Key trends
• 6.2 Diabetes
• 6.3 Obesity
• 6.4 Cardiovascular
• 6.5 Mental & Behavioral health
• 6.6 Hypertension
• 6.7 Insomnia
• 6.8 Others

Chapter 7 Market, By Sales Channel, 2018 - 2032 (USD Million)

• 7.1 Key trends
• 7.2 Business-to-Business (B2B)
• 7.3 Business-to-Consumers (B2C)

Chapter 8 Market, By Region, 2018 - 2032 (USD Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
• 8.6 MEA
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia

Chapter 9 Company Profiles

• 9.1 Otsuka Holdings Co., Ltd
• 9.2 LifeScan Inc.
• 9.3 Teladoc Health
• 9.4 Omada Health Inc.
• 9.5 Pear Therapeutics, Inc.
• 9.6 Propeller Health (ResMed)
• 9.7 Teladoc Health